Kymera Therapeutics, Inc.

NASDAQ:KYMR

Biotechnology

Healthcare
$121.13 +1.67%

+$1.50 today

Market cap
$10.34B
Beta
2.03
P/E (TTM)
-28.3
EPS (TTM)
-$3.23
52W Low $36.65High $103.00

Volume 0.68M

Average 0.58M

KYMR Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Kymera Therapeutics, Inc.NASDAQ: KYMR

Weighted Avg Shares (Diluted) · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares (diluted) growth accelerates

Q2 FY2026 weighted avg shares (diluted) of 98.18M shares rose 22.0% year over year, ahead of the +16.0% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.7% from the prior quarter. Over 3 fiscal years it compounded at +16.1% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +22.0% holds above the trailing-twelve-month pace of +16.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
98.18M+0.7% QoQ
Last fiscal yearDec 2025
84.39M+12.5% YoY
LTMJun 2026
91.85M+16.0% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+22.0%——
1 year+12.5%——
3-year CAGR+16.1%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
84.39M USD
Year-over-year change
+12.5%
4-year CAGR
+15.2%

Weighted Avg Shares (Diluted) vs competitors

How KYMR compares with its peers on the latest reported figures

  • KYMR's LTM Jun 2026 weighted avg shares (diluted) of 91.85M shares is the 3rd highest of the 5 companies compared; the peer median is 85.26M shares.
  • Its year-over-year change of +16.0% is the 3rd highest of 5, against a peer median of +15.2%.
  • Over three fiscal years its annual growth of +16.1% compares with a peer median of +20.0%.
KYMR Competitors Peer median
Weighted Avg Shares (Diluted) for KYMR and competitors
Company Period LTM YoY 3-year CAGR
NRIXNurix Therapeutics, Inc.LTM Aug 2026108.1M +31.0%+21.3%
CCCCC4 Therapeutics, Inc.LTM Mar 202696.61M +38.1%+19.3%
KYMRKymera Therapeutics, Inc.LTM Jun 202691.85M +16.0%+16.1%
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 202673.92M -0.7%+20.7%
ARVNArvinas, Inc.LTM Mar 202668.7M -4.8%+6.9%
Peer median (excluding KYMR) 85.26M+15.2%+20.0%

Competitors are the stored peer set for KYMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue72.83M46.83M78.59M47.07M39.2M
Cost of Revenue00000
Gross Profit72.83M46.83M78.59M47.07M39.2M
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development137.02M164.25M189.08M240.25M316.6M
Selling, General & Admin36.35M43.83M55.04M63.53M68.2M
Operating Expenses173.36M208.08M244.12M308.71M388.6M
Depreciation & Amortization2.4M2.98M3.57M7.37M8.31M
EBITDA(97.65M)(151.66M)(143.2M)(216.24M)(303.06M)
EBITDA Margin-134.1%-323.9%-182.2%-459.4%-773.1%
Operating Income(100.53M)(161.26M)(165.53M)(261.64M)(349.4M)
Operating Margin-138.0%-344.4%-210.6%-555.8%-891.3%
Interest Income488K6.62M18.76M38.03M38.03M
Interest Expense175K176K196K249K249K
Other Income / Expenses313K6.45M18.57M37.78M37.78M
Income Before Tax(100.22M)(154.81M)(146.96M)(223.86M)(311.62M)
Pre-Tax Margin-137.6%-330.6%-187.0%-475.6%-795.0%
Income Tax Expense00000
Net Income(100.22M)(154.81M)(146.96M)(223.86M)(311.4M)
Net Margin-137.6%-330.6%-187.0%-475.6%-794.4%
EPS (Basic)(2.09)(2.87)(2.52)(2.98)(3.69)
EPS (Diluted)(2.09)(2.87)(2.52)(2.98)(3.69)
Weighted Avg Shares47.99M53.93M58.37M75.04M84.39M
Weighted Avg Shares (Diluted)47.99M53.93M58.37M75.04M84.39M

Kymera Therapeutics, Inc.

NASDAQ:KYMR

Intrinsic Alpha fair value

Locked

Current Price

$121.13

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.